Bristol Myers Sqibb News (NYSE:BMY)

12/18/20176:59AMBWBristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Yervoy (ipilimumab) for the Treatment of Pediatr...
First positive CHMP opinion for an immuno-oncology agent for pediatric patients Bristol-Myers Squibb Company (NYSE:BMY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Yervoy (ipilimumab) for pediatric patients 12 years of age... More...>>
12/13/20176:30PMBWBristol-Myers Squibb Granted Exclusive License by Ono Pharmaceutical for Multiple Programs Targeting Immuno-Suppressive Facto...
Bristol-Myers Squibb to develop and commercialize ONO-4578, Ono’s Phase 1 selective Prostaglandin E2 (PGE2) receptor 4 (EP4) antagonist Strengthens Bristol-Myers Squibb’s oncology development program with potential to expand and enhance the benefit of immunotherapy in a broad range of tumor indications Expands companies’... More...>>
12/13/20175:28PMBWU.S. Food & Drug Administration (FDA) Accepts Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilim...
The Opdivo plus Yervoy combination previously received FDA Breakthrough Therapy Designation Application based on results from phase 3 CheckMate -214 study Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application... More...>>
12/11/201710:30AMBWSeattle Genetics & Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study Evaluating the Combination of ADCETRIS...
-Data Presented in Oral Session at the American Society of Hematology (ASH) Annual Meeting with Simultaneous Publication in Blood- -Combination Data Showed 83 Percent Objective Response Rate and 62 Percent Complete Response Rate with an Acceptable Safety Profile in Pre-Transplant Relapsed or Refractory Classical Hodgkin... More...>>
12/09/20179:30AMBWSprycel (dasatinib) Added to Standard Chemotherapy Demonstrates Three-Year Survival Benefit in Pediatric Patients with Newly ...
Showed event-free and overall survival rates of 65.5% and 91.5%, respectively 14.2% of patients treated with Sprycel induction therapy received stem cell transplant in first remission Bristol-Myers Squibb Company (NYSE:BMY) today announced data from the phase 2 CA180-372 study in pediatric patients with newly diagnosed... More...>>
12/07/20174:15PMBWBristol-Myers Squibb Announces Dividend Increase
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared an increase of 2.6% percent in the company’s quarterly dividend, beginning in the first quarter of 2018. The dividend increase will result in a quarterly dividend of 40 cents ($0.40) per share on the $.10 par value Common Stock of the corporation... More...>>
11/30/20177:00PMBWCheckMate -078, a Pivotal, Multinational Phase 3 Opdivo (nivolumab) Lung Cancer Trial with Predominantly Chinese Patients, St...
Opdivo demonstrates superior overall survival compared to docetaxel in patients with previously treated advanced non-small cell lung cancer First I-O agent to show survival benefit in Chinese population, based on a Phase 3 study China Food and Drug Administration accepted the marketing application for Opdivo Bristol-Myers... More...>>
11/30/20174:59PMBWBristol-Myers Squibb to Take Part at the Citi 2017 Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Citi 2017 Global Healthcare Conference on Wednesday, December 6, 2017, in New York. Murdo Gordon, chief commercial officer, will answer questions about the company at 2:55 p.m. ET. Investors and the general public are invited to listen to a live webcast of the... More...>>
11/29/20174:15PMBWBristol-Myers Squibb to Present New Data Across a Broad Range of Blood Cancers at the 59th Annual Meeting & Exposition of the...
Seven company oral presentations include first disclosure of data from CheckMate -205, evaluating Opdivo (nivolumab) as frontline therapy in newly-diagnosed, untreated patients with advanced-stage classical Hodgkin lymphoma Phase 2 data from study CA180-372 evaluating Sprycel (dasatinib) in newly-diagnosed pediatric acute... More...>>
11/28/20176:59AMBWBristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Neutrolis, Remora Therapeutics
Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today announced that Neutrolis and Remora Therapeutics are the winners of Bristol-Myers Squibb’s 2017 Golden Tickets for LabCentral. As a platinum sponsor of... More...>>
11/28/20176:40AMBWEuropean Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) Plus Yervoy...
Application is based on results from the Phase 3 CheckMate -214 study Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which seeks to expand the current indications for Opdivo (nivolumab) plus Yervoy (ipilimumab) to include the... More...>>
11/22/20176:59AMBWBristol-Myers Squibb to Take Part in Evercore ISI Biopharma Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Evercore ISI Biopharma Conference on Wednesday, November 29, 2017, in Boston. Fouad Namouni, senior vice president, head of Oncology Development, will answer questions about the company at 11:45 a.m. ET. Investors and the general public are invited to listen... More...>>
11/11/20175:54PMPRNUSFirst Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma an...
First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative Status, Revealed at SITC 2017 Interim data from the dose-escalation phase of the PIVOT-02 trial highlighted as an oral presentation... More...>>
11/10/20174:13PMBWBMS-Pfizer Alliance to Unveil Real-World Data Analyses - Cost, Safety & Comparative Effectiveness Findings Associated with Or...
Analyses from RWD program, ACROPOLIS, use two large U.S. databases to provide insights on Eliquis® (apixaban), warfarin, and other direct oral anticoagulants in patients with NVAF at 2017 American Heart Association (AHA) Scientific Sessions Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) plan to release... More...>>
11/10/20177:00AMBWEncouraging Response Observed with Opdivo (nivolumab) Plus Investigational IDO1 Inhibitor, BMS-986205, in Heavily Pre-Treated...
First disclosure of anti-tumor activity from the bladder and cervical cancer cohorts showed objective response rates of 32% and 14%, respectively, and was 46% and 25% in patients who express PD-L1 ≥1% Increased proliferating cytotoxic T cell count and decreased kynurenine production were also observed, providing evidence... More...>>
11/10/20176:30AMBWU.S. Food & Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia ...
Sprycel is the first and only second-generation tyrosine kinase inhibitor approved for children with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase Approval based on data from the largest prospective trial in pediatric chronic myeloid leukemia in chronic phase1 Bristol-Myers Squibb Company (NYSE:BMY... More...>>
11/09/20178:00AMBWBristol-Myers Squibb & Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdiv...
Study marks the first clinical experience evaluating an anti-CSF-1 receptor antibody with an anti-PD-1/PD-L1 therapy Early efficacy signal observed in heavily pretreated patients with advanced pancreatic cancer with microsatellite stable (MSS) disease Bristol-Myers Squibb Company (NYSE:BMY) and Five Prime Therapeutics... More...>>
11/08/20176:59AMBWBristol-Myers Squibb to Take Part in Jefferies London Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will take part in the Jefferies London Healthcare Conference on Wednesday, November 15, 2017, in London. John Elicker, senior vice president, Corporate Affairs and Investor Relations, will answer questions about the company at 10:40 a.m. GMT. Investors and the general public are... More...>>
11/07/20178:35AMBWOpdivo Plus Yervoy Combination Delivered Overall Survival Benefit Across PD-L1 Expression Levels in Intermediate- & Poor-Risk...
Results also show that patients reported significantly better kidney cancer symptom control in the Opdivo (nivolumab) plus Yervoy (ipilimumab) arm compared to the sunitinib arm Bristol-Myers Squibb Company (NYSE:BMY) announced today results from a new exploratory analysis of the phase 3 CheckMate -214 trial evaluating... More...>>
11/07/20178:00AMBWBristol-Myers Squibb to Highlight Clinical & Translational Research at the Society for Immunotherapy of Cancer (SITC) 32nd An...
Overall survival data across PD-L1 expression levels in first-line renal cell carcinoma for Opdivo plus Yervoy combination to be presented Data on key pipeline assets, including late-breaking findings on IDO1 inhibitor BMS-986205 plus Opdivo in advanced cancers, and first disclosures of the Company’s OX40 agonist and... More...>>
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:41 V:us D:20171218 13:00:43